Member Info for BuenaVista

The cash may last into Q1 2025 but the revenue situation will need to be sorted out well before then, say Q3 2024, as to reach Q3 with cash running out would severely weaken Destiny's negotiating position.

Just speculators and traders expecting a quick profit exiting. Good buying opportunity for LTHs, although it's uncertain where this dip will bottom out.

It depends how FMcL defines 'started'. Started to prepare for, started to screen, started to dose???

We will get an RNS when the first patient has been dosed and that's the only started that matters.

Where did he say that?

I can't see AVA6000 data being presented until the April conference when Phase 1 Arm1 should have completed and there should be preliminary indications from Arm 2 available.

Companies are even today announcing that they will be presenting at the J P Morgan Healthcare Conference so it's still not too late for Avacta to make a formal announcement. I'm sure the key Avacta people will be attending anyway and will have set up meetings to discuss AVA6000 and the pre|CISION platform.

Tut tut. Everyone knows Alan loves a Thursday RNS.

Lots of green boxes from the usual trolls and the uber-ramper and nothing of interest. This BB has been ruined by engaging with the trolls, who any decently researched investor knows are just liars. Only the immature or insecure feel the need to engage with them.

👋Bye until there's some news.

Just a troll. Ignore.

Deals always take a lot longer than hoped for.

Overview

At Loxo@Lilly, our goal is to create an industry leading pipeline consisting of medicines with the potential to make meaningful differences in the lives of cancer patients. We are actively seeking partnerships with world-class industry and academic collaborators in order to optimize and accelerate the development of new cancer medicines.

Business Development

We believe that good drugs can come from anywhere and are actively looking for opportunities across discovery and development that align with our areas of interest.

https://www.loxooncology.com/partners

I think your chance of that is better than 50%.

I can name several companies where the PIs are convinced they've come across a hidden goldmine but the fact is that for the past year or more the investment environment has been very risk-averse (inflation, 'cost of living crisis', mortgage rates) and AIM is really a very small backwater.

Actually, the transaction was NOT all about GC012F......................

27 December 2023

AstraZeneca to acquire Gracell, furthering cell therapy

Includes clinical-stage autologous BCMA/CD19 CAR-T therapy targeting haematologic malignancies and autoimmune diseases, and proprietary cell therapy manufacturing platform

AstraZeneca has entered into a definitive agreement to acquire Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune diseases, furthering the AstraZeneca cell therapy ambition.

The proposed acquisition will enrich AstraZenecaÕs growing pipeline of cell therapies with GC012F, a novel, clinical-stage FasTCAR-enabled BCMA and CD19 dual-targeting autologous chimeric antigen receptor T-cell (CAR-T) therapy, a potential new treatment for multiple myeloma, as well as other haematologic malignancies and autoimmune diseases including systemic lupus erythematosus (SLE).

Autologous CAR-T is a type of cell therapy created by reprogramming a patientÕs immune T cells to target disease-causing cells, and the manufacturing process for this type of treatment is complex and time-consuming. The Gracell FasTCAR platform significantly shortens manufacturing time, enhances T cell fitness, and will potentially improve the effectiveness of autologous CAR-T treatment in patients. Future applications of this technology may also include rare diseases.

And the terms of the acquisition................................

The upfront cash portion of the consideration represents a transaction value of approximately $1.0bn, a 62% premium to GracellÕs closing market price on 22nd December 2023 and a 154% premium to the 60-day volume-weighted average price (VWAP) of $3.94 before this announcement. Combined, the upfront and potential contingent value payments represent, if achieved, a transaction value of approximately $1.2bn, an 86% premium to Gracell's closing market price on 22nd December 2023 and a 192% premium to the 60-day VWAP. As part of the transaction, AstraZeneca will acquire the cash, cash equivalents and short-term investments on GracellÕs balance sheet, which totalled $234.1m as of 30th September 2023.

https://www.lse.co.uk/rns/AZN/astrazeneca-acquires-gracell-w06r4e3oam8xu02.html

I hope it's not Trump's stinky ketchup sauce

You really are a pathetic. Get a life you little worm.

Link, or it's all BS.

(Why do you expect people to go and search for the programme themselves?🤷🏻‍♂️)

20p

It's a pity the Tories, the party of industry can't sort this out.

Oh wait, they're only interested in helping the big companies that are their 'donors'.

Wishing everyone a happy, healthy and prosperous 2024!

Wishing everyone a happy, healthy and prosperous 2024.